Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Beigene Ltd ADR (NQ: BGNE )

223.81 -3.24 (-1.43%)
Streaming Delayed Price Updated: 1:02 PM EDT, Oct 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 130,776
Open 223.43
Bid (Size) 223.58 (2)
Ask (Size) 224.27 (18)
Prev. Close 227.05
Today's Range 221.47 - 225.76
52wk Range 126.97 - 248.16
Shares Outstanding 1,211,067,023
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
US Listed Chinese Stocks Dominate Another Week - Li Auto, JD.com Among Top 10 Large Cap Gainers Last Week (Sept 30-Oct 4): Are The Others In Your Portfolio?
Best performing large-cap stocks in the past week were mostly USA listed Chinese stocks due to additional stimulus measures to boost China's economy. 
Via Benzinga
Active Biotech Alert: FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:ABBV),(NASDAQ:BGNE),(NASDAQ:HCM),(NASDAQ:ELVN) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety

Performance

YTD
+26.45%
+26.45%
1 Month
+13.93%
+13.93%
3 Month
+51.47%
+51.47%
6 Month
+61.71%
+61.71%
1 Year
+28.48%
+28.48%

More News

Read More
BeiGene Provides Update on FDA Advisory Committee Vote on Benefit-Risk Profile of PD-1 Inhibitors, including TEVIMBRA®, for Treatment of ESCC and Gastric/GEJ Cancers
From BeiGene, Ltd.
Via Business Wire
What Analysts Are Saying About BeiGene Stock
Via Benzinga
Top 2 Health Care Stocks That May Plunge In August
Via Benzinga
Global Oncology Innovator BeiGene Appoints Shalini Sharp to Board of Directors
From BeiGene, Ltd.
Via Business Wire
FDA Casts Doubt On Use Of Merck, Bristol Myers' PD-1 Cancer Drugs For Certain Type Of Gastric Cancer Patients
Via Benzinga
Exposures Product Safety
Chinese Biotech BeiGene Labeled 'Unique Investment' As Analyst Confident In Lead Cancer Drug
Via Benzinga
Oxford Industries Reports Weak Results, Joins Viper Energy And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Why Champions Oncology Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket
Via Benzinga
BeiGene Announces Updates to Commercial Leadership Team
From BeiGene, Ltd.
Via Business Wire
Innovent Bio hopes for plus-sized profits from obesity drug
Via Benzinga
Topics Retirement
Exposures Pension
Week In Review: UCB Sells China Drug Portfolio To CBC For $680 Million
Via Talk Markets
BeiGene to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
From BeiGene, Ltd.
Via Business Wire
BeiGene’s BGB-16673 Receives U.S. FDA Fast Track Designation for CLL/SLL
From BeiGene, Ltd.
Via Business Wire
Cancer Medicines From Merck, Bristol Myers And BeiGene In Question, As FDA Committee To Discuss Limiting PD-1 Drugs For Stomach Cancer
Via Benzinga
Exposures Product Safety
BeiGene Enters Next Phase of Global Growth with Announcement of Second Quarter 2024 Financial Results and Corporate Updates
From BeiGene
Via Business Wire
Week In Review: Nanjing Triastek Partners With BioNTech In A $1.2 Billion Drug Development Deal
Via Talk Markets
BeiGene Opens Flagship U.S. Biologics Manufacturing and Clinical R&D Facility, Continues Global Expansion to Deliver Medicines to More Patients Around the World
From BeiGene, Ltd.
Via Business Wire
AbbVie Could Soar 24%, According to a Wall Street Analyst. Is the High-Yield Dividend Stock a Buy Now?
Via The Motley Fool
BeiGene Announces Appointment of Aaron Rosenberg as Chief Financial Officer
From BeiGene, Ltd.
Via Business Wire
Moderna And Walgreens Boots Alliance Were Among The 10 Biggest Large Cap Losers Last Week (June 23 - June 29): Are These In Your Portfolio?
Via Benzinga
What's Going On With Small-Cap Cancer Focused Nurix Therapeutics On Monday?
Via Benzinga
Week In Review: Osaka Enters $445 Million Deal For Two Hearing Loss Candidates From France's Cilcare
Via Talk Markets
BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024
From BeiGene, Ltd.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.